ABSTRACT
Objective: Epidemiological evidence shows that the prevalence of patients with comorbidity of diabetes mellitus (DM), in Coronavirus disease 2019 (COVID-19) is remarkable and they have poor prognosis. We aimed to investigate the comorbidity of diabetes and covid-19 in positive Polymerase Chain Reaction people in Yazd. Materials and Methods: This retrospective cohort study included data of 570 COVID-19 positive patients, admitted to Shahid Sadoughi Hospital in Yazd, Iran, from February2019 to May 2020, including demographic data and clinical outcome of COVID-19. Study data were analyzed using SPSS software-22 and T-test, Chi-square and a binary logistic regression model were used for modeling. Results: Prevalence of COVID-19 patients with diabetes was 27% and the percentage of male patients was 62.6%. Additionally, duration of hospitalization significantly higher in diabetic patients (P= 0.004), need to invasive mechanical ventilation in diabetic patients was significantly higher than non-diabetic patients (P= 0.001). Conclusion: DM is one of the most important comorbidity with COVID-19 patients and this comorbidity affects the severity of the disease and the outcome of patients. [ FROM AUTHOR] Copyright of Iranian Journal of Diabetes & Obesity (IJDO) is the property of Yazd Diabetes Research Center and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
Background: Among the medications administered for the management of COVID-19 patients, the induction drugs used for intubation have received little attention. The aim of this study was to compare the effect of induction drugs on the mortality of patients with COVID-19 requiring intubation. Methods: In this retrospective study, all patients who were admitted to Shahid Sadoughi and Shahid Rahnemoun hospitals in Yazd from February to March 2020 with definitive diagnosis of COVID-19 and needed intubation were enrolled. Patients were divided into 4 groups based on the type of drugs used in intubation, and mortality rate was assessed at the end of the first, second, fourth, and seventh days of the study. Statistical analyses were performed using SPSS 20 and P values <.05 was considered significant. Results: In this study, 76 patients were examined. Patients were divided into 4 groups, of which 21 were in etomidate group, 8 in ketamine group, 21 in sodium thiopental group, and 35 in midazolam group. Mortality rate in these 4 groups was 25%, 12.5%, 14.3%, and 14.3% (p=0.822), respectively at the end of the first day after intubation; it was 83.3%, 12.5%, 28.6%, and 25.7% (p=0.001), respectively, at the end of the second day; it was 83.3%, 12.5%, 42.9%, and 42.9% (p=0.015), respectively, until the end of the fourth day; it was 100%, 25%, 61.9%, and 65.7% (p=0.007), respectively, until the end of the seventh day. Admission to intubation time interval was 0.91±0.99, 3.12±1.95, 4.09±2.44, and 4.74±2.62 days, respectively (p<0.001). Conclusion: The results of this study suggest that the use of etomidate may be associated with higher mortality in COVID-19 patients. Further studies are needed to verify the results of this study.